These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
162 related articles for article (PubMed ID: 32189965)
1. Intranasal Delivery of Immunotherapeutic Nanoformulations for Treatment of Glioma Through in situ Activation of Immune Response. Yin P; Li H; Ke C; Cao G; Xin X; Hu J; Cai X; Li L; Liu X; Du B Int J Nanomedicine; 2020; 15():1499-1515. PubMed ID: 32189965 [TBL] [Abstract][Full Text] [Related]
2. Intranasal Delivery of Temozolomide-Conjugated Gold Nanoparticles Functionalized with Anti-EphA3 for Glioblastoma Targeting. Wang L; Tang S; Yu Y; Lv Y; Wang A; Yan X; Li N; Sha C; Sun K; Li Y Mol Pharm; 2021 Mar; 18(3):915-927. PubMed ID: 33417456 [TBL] [Abstract][Full Text] [Related]
3. Codelivery of temozolomide and siRNA with polymeric nanocarrier for effective glioma treatment. Peng Y; Huang J; Xiao H; Wu T; Shuai X Int J Nanomedicine; 2018; 13():3467-3480. PubMed ID: 29942129 [TBL] [Abstract][Full Text] [Related]
4. Combination of levetiracetam and IFN-α increased temozolomide efficacy in MGMT-positive glioma. Ni XR; Guo CC; Yu YJ; Yu ZH; Cai HP; Wu WC; Ma JX; Chen FR; Wang J; Chen ZP Cancer Chemother Pharmacol; 2020 Dec; 86(6):773-782. PubMed ID: 33074386 [TBL] [Abstract][Full Text] [Related]
5. Temozolomide-based sonodynamic therapy induces immunogenic cell death in glioma. Zhou Y; Jiao J; Yang R; Wen B; Wu Q; Xu L; Tong X; Yan H Clin Immunol; 2023 Nov; 256():109772. PubMed ID: 37716612 [TBL] [Abstract][Full Text] [Related]
6. Bortezomib inhibits growth and sensitizes glioma to temozolomide (TMZ) via down-regulating the FOXM1-Survivin axis. Tang JH; Yang L; Chen JX; Li QR; Zhu LR; Xu QF; Huang GH; Zhang ZX; Xiang Y; Du L; Zhou Z; Lv SQ Cancer Commun (Lond); 2019 Dec; 39(1):81. PubMed ID: 31796105 [TBL] [Abstract][Full Text] [Related]
7. Development of transferrin-modified poly(lactic-co-glycolic acid) nanoparticles for glioma therapy. Mao J; Meng X; Zhao C; Yang Y; Liu G Anticancer Drugs; 2019 Jul; 30(6):604-610. PubMed ID: 30855310 [TBL] [Abstract][Full Text] [Related]
8. Temozolomide combined with PD-1 Antibody therapy for mouse orthotopic glioma model. Dai B; Qi N; Li J; Zhang G Biochem Biophys Res Commun; 2018 Jul; 501(4):871-876. PubMed ID: 29758196 [TBL] [Abstract][Full Text] [Related]
9. [Intranasal administration of temozolomide for brain-targeting delivery: therapeutic effect on glioma in rats]. Li Y; Gao Y; Liu G; Zhou X; Wang Y; Wang Y; Ma L Nan Fang Yi Ke Da Xue Xue Bao; 2014 May; 34(5):631-5. PubMed ID: 24849425 [TBL] [Abstract][Full Text] [Related]
10. [Establishment of a mouse model bearing orthotopic temozolomide-resistant glioma]. Shi L; Li H; Gu J; Song C; Li J; Chen L; Zhou Q; Qi S; Lu Y Nan Fang Yi Ke Da Xue Xue Bao; 2021 Jan; 41(1):69-74. PubMed ID: 33509755 [TBL] [Abstract][Full Text] [Related]
11. Perillyl alcohol for the treatment of temozolomide-resistant gliomas. Cho HY; Wang W; Jhaveri N; Torres S; Tseng J; Leong MN; Lee DJ; Goldkorn A; Xu T; Petasis NA; Louie SG; Schönthal AH; Hofman FM; Chen TC Mol Cancer Ther; 2012 Nov; 11(11):2462-72. PubMed ID: 22933703 [TBL] [Abstract][Full Text] [Related]
12. Blocking NHE1 stimulates glioma tumor immunity by restoring OXPHOS function of myeloid cells. Hasan MN; Luo L; Ding D; Song S; Bhuiyan MIH; Liu R; Foley LM; Guan X; Kohanbash G; Hitchens TK; Castro MG; Zhang Z; Sun D Theranostics; 2021; 11(3):1295-1309. PubMed ID: 33391535 [No Abstract] [Full Text] [Related]
13. Efficacy of Temozolomide-Conjugated Gold Nanoparticle Photothermal Therapy of Drug-Resistant Glioblastoma and Its Mechanism Study. Yu Y; Wang A; Wang S; Sun Y; Chu L; Zhou L; Yang X; Liu X; Sha C; Sun K; Xu L Mol Pharm; 2022 Apr; 19(4):1219-1229. PubMed ID: 35262365 [TBL] [Abstract][Full Text] [Related]
15. Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model. Banissi C; Ghiringhelli F; Chen L; Carpentier AF Cancer Immunol Immunother; 2009 Oct; 58(10):1627-34. PubMed ID: 19221744 [TBL] [Abstract][Full Text] [Related]
16. Systemic delivery of neutralizing antibody targeting CCL2 for glioma therapy. Zhu X; Fujita M; Snyder LA; Okada H J Neurooncol; 2011 Aug; 104(1):83-92. PubMed ID: 21116835 [TBL] [Abstract][Full Text] [Related]
17. Medium dose intermittent cyclophosphamide induces immunogenic cell death and cancer cell autonomous type I interferon production in glioma models. Du B; Waxman DJ Cancer Lett; 2020 Feb; 470():170-180. PubMed ID: 31765733 [TBL] [Abstract][Full Text] [Related]
18. Convection-enhanced delivery of temozolomide and whole cell tumor immunizations in GL261 and KR158 experimental mouse gliomas. Enríquez Pérez J; Kopecky J; Visse E; Darabi A; Siesjö P BMC Cancer; 2020 Jan; 20(1):7. PubMed ID: 31900109 [TBL] [Abstract][Full Text] [Related]
19. All-stage precisional glioma targeted therapy enabled by a well-designed D-peptide. Ran D; Zhou J; Chai Z; Li J; Xie C; Mao J; Lu L; Zhang Y; Wu S; Zhan C; Lu W Theranostics; 2020; 10(9):4073-4087. PubMed ID: 32226540 [TBL] [Abstract][Full Text] [Related]
20. In vitro and in vivo Study on Glioma Treatment Enhancement by Combining Temozolomide with Calycosin and Formononetin. Ni Q; Fan Y; Zhang X; Fan H; Li Y J Ethnopharmacol; 2019 Oct; 242():111699. PubMed ID: 31005632 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]